Amino-Terminal Pro-B-Type Natriuretic Peptides: Testing in General Populations

American Journal of Cardiology

Volumn 101, Issue 3 SUPPL., 2008, Pages

  de Lemos, James A ^a   Hildebrandt, Per ^b  

^a UNIVERSITY OF TEXAS AT DALLAS   (United States)

^b ROSKILDE HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE;

ARTICLE; COMPARATIVE STUDY; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; MASS SCREENING; POPULATION; PREDICTION; PRIORITY JOURNAL;

BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; HUMANS; MASS SCREENING; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PROTEIN PRECURSORS;

EID: 38649131778     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2007.11.014     Document Type: Article

References (22)

1. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 327 (1992) 685-691
2. Devereux R.B., Wachtell K., Gerdts E., Boman K., Nieminen M.S., Papademetriou V., Rokkedal J., Harris K., Aurup P., and Dahlof B. Prognostic significance of left ventricular mass change during treatment of hypertension. JAMA 292 (2004) 2350-2356
3. Kistorp C., Raymond I., Pedersen F., Gustafsson F., Faber J., and Hildebrandt P. N-terminal pro-brain natriuretic peptide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults. JAMA 293 (2005) 1609-1616
4. Galasko G., Lahiri A., Barnes S.C., Collinson P., and Senior R. What is the normal range for N-terminal pro-brain natriuretic peptide?. How well does this normal range screen for cardiovascular disease?. Eur Heart J 26 (2005) 2269-2276
5. Costello-Boerrigter L.C., Boerrigter G., Redfield M.M., Rodeheffer R.J., Urban L.H., Mahoney D.W., Jacobsen S.J., Heublein D.M., and Burnett Jr. J.C. Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide in the general community: determinants and detection of left ventricular dysfunction. J Am Coll Cardiol 47 (2006) 345-353
6. Olsen M.H., Hansen T.W., Christensen M.K., Gustafsson F., Rasmussen S., Wachtell K., Borch-Johnsen K., Ibsen H., Jorgensen T., and Hildebrandt P. N-terminal pro brain natriuretic peptide is inversely related to metabolic cardiovascular risk factors and the metabolic syndrome. Hypertension 46 (2005) 660-666
7. Wang T.J., Larson M.G., Levy D., Benjamin E.J., Leip E.P., Wilson P.W., and Vasan R.S. Impact of obesity on plasma natriuretic peptide levels. Circulation 109 (2004) 594-600
8. McCord J., Mundy B.J., Hudson M.P., Maisel A.S., Hollander J.E., Abraham W.T., Steg P.G., Omland T., Knudsen C.W., Sandberg K.R., and McCullough P.A. Relationship between obesity and B-type natriuretic peptide levels. Arch Intern Med 164 (2004) 2247-2252
9. Krauser D.G., Lloyd-Jones D.M., Chae C.U., Cameron R., Anwaruddin S., Baggish A.L., Chen A., Tung R., and Januzzi Jr. J.L. Effect of body mass index on natriuretic peptide levels in patients with acute congestive heart failure: a ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) substudy. Am Heart J 149 (2005) 744-750
10. Taylor J.A., Christenson R.H., Rao K., Jorge M., and Gottlieb S.S. B-type natriuretic peptide and N-terminal pro B-type natriuretic peptide are depressed in obesity despite higher left ventricular end diastolic pressures. Am Heart J 152 (2006) 1071-1076
11. Das S.R., Drazner M.H., Dries D.L., Vega G.L., Stanek H.G., Abdullah S.M., Canham R.M., Chung A.K., Leonard D., Wians Jr. F.H., and de Lemos J.A. Impact of body mass and body composition on circulating levels of natriuretic peptides: results from the Dallas Heart Study. Circulation 112 (2005) 2163-2168
12. Redfield M.M., Rodeheffer R.J., Jacobsen S.J., Mahoney D.W., Bailey K.R., and Burnett Jr. J.C. Plasma brain natriuretic peptide concentration: impact of age and gender. J Am Coll Cardiol 40 (2002) 976-982
13. Chang A.Y., Abdullah S.M., Jain T., Stanek H.G., Das S.R., McGuire D.K., Auchus R.J., and de Lemos J.A. Associations among androgens, estrogens, and natriuretic peptides in young women: observations from the Dallas Heart Study. J Am Coll Cardiol 49 (2007) 109-116
14. Das S.R., Drazner M.H., Abdullah S.M., Khera A., McGuire D.K., and de Lemos J.A. Natriuretic peptides and renal function: from the Dallas Heart Study [abstract]. Circulation 112 suppl II (2005) II-670
15. Vasan R.S., Benjamin E.J., Larson M.G., Leip E.P., Wang T.J., Wilson P.W., and Levy D. Plasma natriuretic peptides for community screening for left ventricular hypertrophy and systolic dysfunction: the Framingham heart study. JAMA 288 (2002) 1252-1259
16. Redfield M.M., Rodeheffer R.J., Jacobsen S.J., Mahoney D.W., Bailey K.R., and Burnett Jr. J.C. Plasma brain natriuretic peptide to detect preclinical ventricular systolic or diastolic dysfunction: a community-based study. Circulation 109 (2004) 3176-3181
17. McDonagh T.A., Robb S.D., Murdoch D.R., Morton J.J., Ford I., Morrison C.E., Tunstall-Pedoe H., McMurray J.J., and Dargie H.J. Biochemical detection of left-ventricular systolic dysfunction. Lancet 351 (1998) 9-13
18. Ng L.L., Loke I.W., Davies J.E., Geeranavar S., Khunti K., Stone M.A., Chin D.T., and Squire I.B. Community screening for left ventricular systolic dysfunction using plasma and urinary natriuretic peptides. J Am Coll Cardiol 45 (2005) 1043-1050
19. Groenning B.A., Raymond I., Hildebrandt P.R., Nilsson J.C., Baumann M., and Pedersen F. Diagnostic and prognostic evaluation of left ventricular systolic heart failure by plasma N-terminal pro-brain natriuretic peptide concentrations in a large sample of the general population. Heart 90 (2004) 297-303
20. Wang T.J., Larson M.G., Levy D., Benjamin E.J., Leip E.P., Omland T., Wolf P.A., and Vasan R.S. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med 350 (2004) 655-663
21. Olsen M.H., Hansen T.W., Christensen M.K., Gustafsson F., Rasmussen S., Wachtell K., Ibsen H., Torp-Pedersen C., and Hildebrandt P.R. N-terminal pro-brain natriuretic peptide, but not high sensitivity C-reactive protein, improves cardiovascular risk prediction in the general population. Eur Heart J 28 (2007) 1374-1381
22. McKie P.M., Rodeheffer R.J., Cataliotti A., Martin F.L., Urban L.H., Mahoney D.W., Jacobsen S.J., Redfield M.M., and Burnett Jr. J.C. Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide: biomarkers for mortality in a large community-based cohort free of heart failure. Hypertension 47 (2006) 874-880